Drug name - Cerdelga

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6916802 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(7 months ago)

US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(3 years from now)

US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615573 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Apr, 2022

(7 months ago)

US7253185 GENZYME CORP Amino ceramide-like compounds and therapeutic methods of use
Apr, 2022

(7 months ago)

US10888547 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Jan, 2031

(8 years from now)

US10888544 GENZYME CORP Methods for treating Gaucher disease
Dec, 2038

(16 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat tartrate); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twice per day); Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with moderate to severe renal impairment; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive metabolizers with mild hepatic impairment and are concurrently taking a strong or moderate cyp3a inhibitor

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 84MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in